鍾大放

1978-03--1982-01 瀋陽藥學院 大學本科，學士學位

1982-02--1984-12 瀋陽藥學院 研究生，碩士學位

1986-09--1989-12 德國波恩大學 研究生，博士學位

1985-01~1986-09,瀋陽藥學院, 助教

1990-01~1994-06,德國藥師中心實驗室, 博士後

1994-07~2005-03,瀋陽藥科大學, 教授

2005-03~現在, 中國科學院上海藥物研究所, 研究員 ^[2] 

1998-2008，國務院學位委員會藥學學科評議組成員

2002-2008，中國質譜學會有機質譜專業委員會主任

1996至今，國家藥典委員會委員

2003至今，中國藥理學會藥物代謝專業委員會副主任

2005至今，中國藥學會藥物分析專業委員會副主任

2012至今，中國生物分析論壇召集人

三種國際期刊Bioanalysis，Biomedical Chromatography，Journal of Chromatography B 編委

藥學學報、中國藥學雜誌、中國藥理學與毒理學雜誌、中國臨牀藥理學雜誌、藥物分析雜誌、中國醫藥工業雜誌、質譜學報編委 ^[1] 

1. 建設符合國際標準的藥物代謝研究平台

2. 生物樣品定量分析方法研究

3. 藥物代謝產物追蹤和結構鑑定

4. 創新藥物代謝和藥動學評價

5. 藥物代謝酶和藥物轉運體相關的體內藥物相互作用機制研究

6. 放射性同位素方法用於藥物代謝研究

7. 抗體藥物藥動學研究 ^[1] 

曾主持7項國家自然科學基金項目，1996年獲國家傑出青年科學基金。他的研究工作導致在亞洲人羣中發現新的突變等位基因CYP2C9*13，並且將其與氯諾昔康和甲苯磺丁脲經CYP2C9代謝清除多態性相關聯。研究工作闡明瞭天然產物魚腥草素、綠原酸和雷公藤內酯醇生物活化機制。

已經發表SCI論文210餘篇（他引2000餘次），國內期刊論文220餘篇（他引2300餘次），出版藥物代謝專著和譯著5部。指導畢業博士生48名，碩士生90餘名。

在中國製定生物分析和藥物代謝法規性指導原則方面發揮了關鍵作用，是中國藥典2015年版《生物樣品定量分析方法驗證指導原則》和《藥物製劑人體生物利用度和生物等效性試驗指導原則》的起草人。 ^[1] 

11/1991 遼寧省科技進步二等獎，排名第二

12/1995 國家教委跨世紀人才培養計劃

12/1996 國家傑出青年科學基金

01/1997 國家教委、人事部全國優秀留學回國人員

10/2001 國務院政府特殊津貼

12/2003 遼寧省科技進步二等獎，排名第一

11/2015 中國藥學會科學技術二等獎，排名第一 ^[1] 

2014-2017國家自然科學基金項目, 雷騰舒代謝產物合成及衍生物類藥性質研究, 項目負責人

2018-2019上海市科委項目, 上海研發公共服務平台，項目負責人

2018-2020中國科學院個性化藥物戰略性先導科技專項，基於個性化藥物的早期ADME技術體系建設，子課題負責人

2016-2021國家自然科學基金創新羣體, 基於納米技術的抗癌藥物新型遞釋系統，子課題負責人 ^[1] 

1.Li XL, Guo ZT, Wang YD, Chen XY, Liu J, Zhong DF*. Potential role of organic anion transporting polypeptide 1B1 in the selective hepatic uptake of hematoporphyrin monomethyl ethyl ether isomers. Acta Pharmacologica Sinica, 2015, 36: 268-280

2.Zhu YT, Deng P, Zhong DF*. Derivatization methods for LC–MS analysis of endogenous compounds. Bioanalysis, 2015, 7:2557-2581

3.Liu C, Chen ZQ, Zhong K, Li L, Zhu WL, Chen XY, Zhong DF*. Human liver cytochrome P450 enzymes and microsomal thiol methyltransferase are involved in the stereoselective formation and methylation of the pharmacologically active metabolite of clopidogrel. Drug Metabolism and Disposition, 2015, 43: 1632-1641

4.Zhu YT, Li L, Deng P, Chen XY, Zhong DF*. Characterization of TPN729 metabolites in humans usingultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2016, 117: 217–226

5.Zhang YF, Dai XJ, Yang Y, Chen XY, Wang T, Tang YB, Tsai CY, Chang LW, Chang YT, Zhong DF*. Effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in healthy Chinese volunteers. Drug Design, Development and Therapy, 2016, 10: 357-370

6.Zhu YT, Li L, Zhang G, Wan H, Yang CY, Diao XX, Chen XY, Zhang LS, Zhong DF*. Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Journal of Chromatography B, 2016, 1033-1034: 117-127

7.Jiang JF, Pang XH, Li L, Dai XJ, Diao XX, Chen XY, Zhong DF*, Wang YW, Chen YW. Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide. Drug Design, Development and Therapy, 2016, 10: 2181-2191

8.Yu MM, Gao ZW, Dai XJ, Gong H, Zhang LS, Chen XY, Zhong DF*, Sy SKB*. Population pharmacokibetic and covariate analysis of apatinib, an oral tyrosine kinase inhibitor, in healthy volunteers and patients with solid tumors. Clinical Pharmacokinetics, 2017, 56: 65-76

9.Zhang YF, Chen XY, Tang YB, Lu YM, Guo LX, Zhong DF*. Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax tablets (70 mg) in fasting, healthy volunteers: a randomized, open-label, three-way, reference-replicated crossover study. Drug Design, Development and Therapy, 2017, 11: 2109-2119

10.Jiang JF, Chen XY, Zhong DF*. Arylacetamide deacetylase is involved in vicagrel bioactivation in humans. Frontiers in Pharmacology, 2017, 8: 846(1-8)

11.Xu Y, Zhang YF, Chen XY, Zhong DF*. CYP3A4 inducer and inhibitor strongly affect the pharmacokinetics of triptolide and its derivative in rats. Acta Pharmacologica Sinica, 2018, 39: 1386-1392

12.Zhang D, Yang CY, Chen XY, Li XL*, Zhong DF*. A bridging immunogenicity assay for monoclonal antibody: case study with SHR-1222. Bioanalysis, 2018, 10: 1115-1117

13.Liu XY, Zhang YF, Chen Q, Zhan Y, Wang QR, Hu CY, Yu C, Guo ZT, Chen XY, Zhong DF*. Pharmacokinetic drug interactions of apatinib with rifampin and itraconazole. Journal of Clinical Pharmacology, 2018, 58: 347-356

14.Liu C, Lu YM, Sun HB, Yang J, Liu YQ, Lai XJ, Gong YC, Liu XF, Li YG, Zhang YF, Chen XY, Zhong DF*. Development and validation of a sensitive and rapid UHPLC-MS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2018, 149: 394-402

15.Jiang JF, Chen XY, Zhong DF*. Predominant contribution of carboxylesterase 1 and 2 in hydrolysis of anordrin in human. Xenobiotica, 2018, 48: 533-540

16.Liu C, Zhang YF, Chen WL, Lu YM, Li W, Liu YQ, Lai XJ, Gong YC, Liu XF, Li YG, Chen XY, Li XN, Sun HB*, Yang J*, Zhong DF*. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. European Journal of Pharmaceutical Sciences, 2019, 127: 151-160

17.Liu XY, Wei Li, Zhang YF, Jiang Y, Zhao QY, Zhong DF*. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2019, 176: 112735

18.Gao YX, Zhang D, Yang CY, Duan XT, Li XL, Zhong DF*. Two validated liquid chromatography-mass spectrometry methods with different pretreatment for the quantification of an anti-CD47 monoclonal antibody in rat and cynomolgus monkey serum comparing with an electrochemiluminescence method. Journal of Pharmaceutical and Biomedical Analysis, 2019, 175: 112792

19.Zhu YT, Teng Z, Li W, Guo LX, Qu XJ, Wang QR, Mao SY, Chen XY, Zhong DF*. Effects of apatinib on the pharmacokinetics of nifedipine and warfarin in patients with advanced solid tumors. Drug Design, Development and Therapy, 2020, 14: 1963-1970

20.Chen ZD, Gao YX, Zhong DF*. Technologies to improve the sensitivity of existing chromatographic methods used for bioanalytical studies. Biomedical Chromatography, 2020, 34: e4798 ^[1]